{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:36:26Z","timestamp":1788294986702,"version":"build-2803163510"},"reference-count":39,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Posterior blepharitis and dry eye are common disorders with meibomian gland dysfunction (MGD), a principal driver of their pathophysiology. Meibomian gland dysfunction is increasingly prevalent in older populations with contributory hormonal imbalances. The abnormal meibum in MGD has been documented to have an excess of cholesterol with a resultant disruption of the lipid layer of the tear film. This leads to tear film instability due to the inadequate trapping of the aqueous portion of the tear film with resultant evaporative dry eye. Significant morbidity may follow MGD with ocular surface inflammation disrupting both social and work function. Rosacea is a common chronic inflammatory condition of the central face but can have ocular and systemic inflammatory associations. It is especially prevalent in North European populations and can have onset at any age, but commonly presents between thirty and fifty years of age. In ocular rosacea, MGD is a recognised manifestation as is dyslipidaemia. Ocular rosacea can predate cutaneous disease. As yet, there is no directly reported evidence of the efficacy of the early identification and treatment of ocular rosacea with associated dyslipidaemia and systemic inflammation. We posit that MGD in ocular rosacea sufferers may be a marker for dysregulated cholesterol synthesis and inflammation, and that statins maybe a potential therapy. This article introduces potential strategies to utilise ocular rosacea MGD as a possible marker for ophthalmologists, cardiologists, and primary healthcare physicians to treat rosacea-associated dyslipidaemia and systemic inflammation. This could aid in overall cardiovascular morbidity and mortality control for rosacea sufferers, potentially at an earlier age, while also addressing their tear film de-stabilisation through cholesterol lowering and inflammation reduction.<\/jats:p>","DOI":"10.3390\/metabo13070811","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T01:14:12Z","timestamp":1688087652000},"page":"811","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rosacea Meibomian Gland Dysfunction Posterior Blepharitis May Be a Marker for Earlier Associated Dyslipidaemia and Inflammation Detection and Treatment with Statins"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-9374","authenticated-orcid":false,"given":"Kenneth G.","family":"Ooi","sequence":"first","affiliation":[{"name":"Corneal Research Group, Discipline of Ophthalmology, Save Sight Institute, Sydney Eye Hospital Campus, Sydney, NSW 2000, Australia"},{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-1765","authenticated-orcid":false,"given":"Stephanie L.","family":"Watson","sequence":"additional","affiliation":[{"name":"Corneal Research Group, Discipline of Ophthalmology, Save Sight Institute, Sydney Eye Hospital Campus, Sydney, NSW 2000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00006324-200007000-00010","article-title":"Prevalence of dry eye subtypes in clinical optometry practice","volume":"77","author":"Albietz","year":"2000","journal-title":"Optom. Vis. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00006324-199009000-00010","article-title":"Prevalence of Meibomian gland dysfunction","volume":"67","author":"Hom","year":"1990","journal-title":"Optom. Vis. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","article-title":"The international workshop on meibomian gland dysfunction: Report of the definition and classification subcommittee","volume":"52","author":"Nelson","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_4","first-page":"282","article-title":"Incidence and prevalence of rosacea: A systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/ijd.14757","article-title":"Rosacea: A wholistic review and update from pathogenesis to diagnosis and therapy","volume":"59","author":"Marson","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_6","first-page":"9","article-title":"Oculocutaneous aspects of rosacea","volume":"62","author":"Starr","year":"1969","journal-title":"Proc. R. Soc. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0161-6420(97)30015-3","article-title":"Ocular rosacea: Patient characteristics and follow-up","volume":"104","author":"Akpek","year":"1997","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ceo.13900","article-title":"Ocular manifestations of rosacea: A clinical review","volume":"49","author":"Tavassoli","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00003226-200304000-00009","article-title":"The prevalence of ocular signs in acne rosacea: Comparing patients from ophthalmology and dermatology clinics","volume":"22","author":"Ghanem","year":"2003","journal-title":"Cornea"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00003226-200009000-00010","article-title":"Changing concepts in the diagnosis and management of blepharitis","volume":"19","author":"McCulley","year":"2000","journal-title":"Cornea"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.ophtha.2013.05.002","article-title":"Meibomian gland dysfunction and hypercholesterolemia","volume":"120","author":"Pinna","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/jdv.12234","article-title":"Rosacea and cardiovascular risk factors: A case control study","volume":"28","author":"Duman","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40257-021-00595-7","article-title":"Rosacea: New Concepts in Classification and Treatment","volume":"22","author":"Arents","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaad.2015.04.028","article-title":"Cardiovascular comorbidities in patients with rosacea: A nationwide case-control study from Taiwan","volume":"73","author":"Hua","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/ICO.0000000000000393","article-title":"Evaluation of dry eye and meibomian gland dysfunction with meibography in patients with rosacea","volume":"34","author":"Palamar","year":"2015","journal-title":"Cornea"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Barbosa, E.B., Tavares, C.M., da Silva, D.F.L., Santos, L.S., Fran\u00e7a, A.F.E.D.C., and Alves, M. (2022). Characterization of meibomian gland dysfunction in patients with rosacea. Arq. Bras. Oftalmol., 86.","DOI":"10.5935\/0004-2749.20230043"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","article-title":"The international workshop on meibomian gland dysfunction: Executive summary","volume":"52","author":"Nichols","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.survophthal.2019.08.007","article-title":"Management of meibomian gland dysfunction: A review","volume":"65","author":"Sabeti","year":"2020","journal-title":"Surv. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0039-6257(96)80064-6","article-title":"Meibomian gland dysfunction","volume":"40","author":"Driver","year":"1996","journal-title":"Surv. Ophthalmol."},{"key":"ref_20","first-page":"4874","article-title":"Effect of androgen deficiency on the human meibomian gland and ocular surface","volume":"85","author":"Krenzer","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ajo.2010.04.016","article-title":"Association of dyslipidemia in moderate to severe meibomian gland dysfunction","volume":"150","author":"Dao","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10792-015-0149-4","article-title":"Singh, Dyslipidemia and its association with meibomian gland dysfunction","volume":"36","author":"Braich","year":"2016","journal-title":"Int. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00417-019-04247-9","article-title":"HMG-CoA reductase expression in human eyelid tissue and in a human meibomian gland epithelial cell line","volume":"257","author":"Ooi","year":"2019","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ceo.13388","article-title":"Association of dyslipidaemia and oral statin use, and dry eye disease symptoms in the Blue Mountains Eye Study","volume":"47","author":"Ooi","year":"2019","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ajo.2020.05.007","article-title":"Association of Dry Eye Disease With Dyslipidemia and Statin Use","volume":"218","author":"Aldaas","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajo.2020.06.029","article-title":"Effect of 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A Reductase Inhibitors on the Meibomian Gland Morphology in Patients with Dyslipidemia","volume":"219","author":"Wu","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","first-page":"1227","article-title":"Association of oral statin use with dry eye symptoms and signs in the DRy Eye Assessment and Management (DREAM\u00a9) Study","volume":"62","author":"Yu","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000367851","article-title":"Efficacy and Safety of Topical Atorvastatin for the Treatment of Dry Eye Associated with Blepharitis: A Pilot Study","volume":"54","author":"Ooi","year":"2015","journal-title":"Ophthalmic Res."},{"key":"ref_29","first-page":"434586","article-title":"Statin Modulation of Human T-Cell Proliferation, IL-1\u03b2 and IL-17 Production, and IFN-\u03b3 T Cell Expression: Synergy with Conventional Immunosuppressive Agents","volume":"2013","author":"Jameel","year":"2013","journal-title":"Int. J. Inflam."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/ICO.0b013e318294b0c0","article-title":"Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire","volume":"32","author":"Ngo","year":"2013","journal-title":"Cornea"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ICO.0b013e31816583f6","article-title":"The Ocular Protection Index","volume":"27","author":"Ousler","year":"2008","journal-title":"Cornea"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exer.2013.05.010","article-title":"Tear film lipids","volume":"117","author":"Butovich","year":"2013","journal-title":"Exp. Eye Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/OPX.0000000000000411","article-title":"Comparison of Tear Lipid Profile among Basal, Reflex, and Flush Tear Samples","volume":"91","author":"Rohit","year":"2014","journal-title":"Optom. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1167\/iovs.09-4609","article-title":"Detection and Quantification of Tear Phospholipids and Cholesterol in Contact Lens Deposits: The Effect of Contact Lens Material and Lens Care Solution","volume":"51","author":"Saville","year":"2010","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"146579","DOI":"10.1155\/2013\/146579","article-title":"Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients","volume":"2013","author":"Barakat","year":"2013","journal-title":"ISRN Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tramacere, I., Boncoraglio, G.B., Banzi, R., Del Giovane, C., Kwag, K.H., Squizzato, A., and Moja, L. (2019). Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: A systematic review and network meta-analysis. BMC Med., 17.","DOI":"10.1186\/s12916-019-1298-5"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jaad.2017.09.016","article-title":"Comorbidities in rosacea: A systematic review and update","volume":"78","author":"Haber","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.semvascsurg.2011.10.005","article-title":"Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein)","volume":"24","author":"Samson","year":"2011","journal-title":"Semin. Vasc. Surg."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/7\/811\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:22Z","timestamp":1760126602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/7\/811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["metabo13070811"],"URL":"https:\/\/doi.org\/10.3390\/metabo13070811","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}